Product How it works Pricing Blog FAQ About Contact
Spyre Therapeutics

Spyre Therapeutics (NASDAQ: SYRE) revenue

Spyre Therapeutics reported revenue of $0.0m for fiscal 2025; in fiscal 2024 it was $0.0m.

Spyre Therapeutics's best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2022, −87.6%.

Revenue, in millions of US dollars4.620165.220173.920180.020190.0202018.720212.320220.920230.020240.02025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$0.0m—−$209.6m—
2024$0.0m−100.0%−$208.6m—
2023$0.9m−62.0%−$242.3m−27,348.0%
2022$2.3m−87.6%−$84.8m−3,640.2%
2021$18.7m—−$65.6m−350.3%
2020$0.0m—−$81.5m—
2019$0.0m−100.0%−$80.3m—
2018$3.9m−25.3%−$45.5m−1,169.3%
2017$5.2m+12.5%−$27.7m−531.7%
2016$4.6m—−$21.9m−473.3%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Spyre Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, Spyre Therapeutics ranks 420th of the 422 US health care companies with a page on Celsmar.

RankCompanyRevenueRevenue growth
418thSpruce Biosciences$0.0m−100.0%
419thScholar Rock$0.0m—
420thSpyre Therapeutics$0.0m—
421stTenax Therapeutics$0.0m—
422ndZentalis Pharmaceuticals$0.0m−100.0%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Spyre Therapeutics

How much revenue did Spyre Therapeutics make in fiscal 2025?
Spyre Therapeutics reported revenue of $0.0m for fiscal 2025, compared with $0.0m in fiscal 2024.
What was the best year for revenue at Spyre Therapeutics?
Of its last 10 fiscal years, fiscal 2021, with $18.7m.
Where does Spyre Therapeutics rank in its sector by revenue?
It ranks 420th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Spyre Therapeutics come from?
From the annual report (Form 10-K) that Spyre Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Spyre Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Spyre Therapeutics: the Spyre Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.